Ritonavir

CHEMBL163 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
720.9 g/mol
LogP
6.0
Phase
4

An antiretroviral drug originally used to treat HIV, now most commonly used at low doses as a pharmacokinetic booster to increase the blood levels of other protease inhibitors and antiviral drugs. By inhibiting the CYP3A4 enzyme, it slows the breakdown of companion drugs and allows them to be taken less frequently.

分子量

720.9000 g/mol

LogP

6.00

TPSA

202.00 Ų

リピンスキーの五則

不適合

治療領域

作用機序

Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1

InChI

InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1

Molecular Formula

C37H48N6O5S2

HBD / HBA

4 / 9

回転可能結合数

18

重原子数

50

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

An antiretroviral drug originally used to treat HIV, now most commonly used at low doses as a pharmacokinetic booster to increase the blood levels of other protease inhibitors and antiviral drugs. By inhibiting the CYP3A4 enzyme, it slows the breakdown of companion drugs and allows them to be taken less frequently.

Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.

Yes, Ritonavir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL163. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 392622. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.